Dry Eye Syndrome Clinical Trials

Dry Eye Syndrome Overview

With nearly 300 million dry eye sufferers worldwide, dry eye represents one of the largest ophthalmic indications. It is also known as keratoconjunctivitis sicca. To date, there is no cure for dry eye syndrome, but there are treatments to control its symptoms. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. A greater risk of acquiring dry eye is also experienced by females, with postmenopausal women being particularly at risk.

In the US alone, the economic burden of dry eye totals USD 3.84 billion in direct annual health care costs. After including the indirect costs of lost productivity, the societal burden of dry eye rises to USD 55.4 billion annually in the US. For patients, the average annual direct cost ranges from USD 678 for patients with mild dry eye to USD 1,267 for severe cases. If pharmaceuticals and punctual plugs are included, the cost for these patients rises to USD 2,959 annually. Furthermore, dry eye increases lost productivity through both absenteeism and decreased presenteeism, with the former ranging from 8.4 to 14.2 days per year depending on severity and the latter ranging from 91 to 128.2 days per year depending on severity.

Recent Developments in Dry Eye Syndrome Market:

Several recent developments have taken place in the field of dry eye syndrome. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2023, Astellas Pharma signed a definitive agreement to acquire Iveric Bio. Under the terms of the agreement, Iveric’s portfolio of retinal disease drugs will be integrated in Astellas’ portfolio of treatments for eye disorder. 
• In May 2023, Viridian Therapeutics entered into a partnership with Enable Injections with an aim to support its preclinical programs outside of thyroid eye disease and enhance patient’s experience. 
• In February 2023, AbbVie entered into a strategic collaboration with Capsida Biotherapeutics in order to develop targeted genetic medicines for eye diseases with high unmet need.

Scope of the Report

The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of dry eye. We have identified a number of such trials which are taking place across multiple geographies. For each specific trial, we have provided the following information:

1. Trial Objective
2. Manufacturer / Licensee
3. Treatment Target
4. Mechanism of Action
5. Sponsor / Collaborator
6. Trial Phase
7. Trial Status
8. Start Date
9. End Date
10. Enrolment
11. Age Group
12. Inclusion Criteria
13. Exclusion Criteria
14. Study Design
15. Primary Endpoint
16. Secondary Endpoint
17. Treatment Arms
18. Route of Administration
19. Location(s)
20. Trial Results (if known)

The above information has also been presented in the form of a dashboard to provide a high level quick overview of the ongoing activity in this space.